Th17 Cells and IL-17 As Novel Immune Targets in Ovarian Cancer Therapy

Figure 4

Comparison of Th17 cells percentage in PB and PF of ovarian cancer (a) and in the group with benign ovarian tumor (b).

(a)

(b)